Loncastuximab tesirine: all 31 studies that test it
Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.
- Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)Not yet recruitingNCT07573436Phase 1/2
- Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT07197307Phase 2
- Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell LymphomaRecruitingNCT06919939Phase 2
- Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy FailureRecruitingNCT06918912Phase 2
- Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)RecruitingNCT06788964Phase 2
- Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)RecruitingNCT06607549Phase 1
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT05991388Phase 2/3
- Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingNCT05672251Phase 2
- A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell TherapyRecruitingNCT05464719Phase 2
- Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT05296070Phase 2
- Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular LymphomaRecruitingNCT04998669Phase 2
- A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT05144009Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular LymphomaTerminatedNCT04699461Phase 2Results posted
- Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaTerminatedNCT03685344Phase 1Results posted
- Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell LymphomaTerminatedNCT03684694Phase 1/2Results posted
- Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT03589469Phase 2Results posted
- Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT02669264Phase 1Results posted
- Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)CompletedNCT02669017Phase 1Results posted
- Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic LeukemiaActive, not recruitingNCT05971251Phase 1
- A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)TerminatedNCT05660395Phase 1
- A Study of MT-2111 in Patients With Relapsed/Refractory DLBCLActive, not recruitingNCT05658562Phase 1/2
- Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell LymphomaActive, not recruitingNCT05600686Phase 2
- Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell MalignanciesTerminatedNCT05453396Phase 2
- Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid MalignanciesActive, not recruitingNCT05270057Phase 1
- Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.Active, not recruitingNCT05249959Phase 2
- Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT05228249Phase 1
- Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post TransplantWithdrawnNCT05222438Phase 2
- Loncastuximab Tesirine in WMActive, not recruitingNCT05190705Phase 2
- Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin LymphomaActive, not recruitingNCT05053659Phase 1
- A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)WithdrawnNCT04974996Phase 1
- Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT04384484Phase 3